Citizens reiterates Summit Therapeutics stock rating after AstraZeneca deal
Covered in this story
What has happened since
- AstraZeneca is down 4.2% since this was published, 5 days ago.
Price move measured from the close nearest publication to the latest quote.
Call it yourself
No calls on $AZN.L yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on AstraZeneca →Summary aggregated from Investing.com's public RSS feed. The full reporting belongs to Investing.com — please read it on their site.